%D8%AF%D8%A7%D9%83%D9%84%D9%8A%D8%B2%D9%88%D9%85%D8%A7%D8%A8%D8%AF%D8%A7%DA%A9%D9%84%DB%8C%D8%B2%D8%A7%D9%85%D8%A7%D8%A8DaclizumabDaclizumab%D8%AF%D8%A7%DA%A9%D9%84%DB%8C%D8%B2%D9%88%D9%85%D8%A8DaclizumabDaclizumabDaklizumabDaklizumabDaklizumab%D0%94%D0%B0%D0%BA%D0%BB%D1%96%D0%B7%D1%83%D0%BC%D0%B0%D0%B1DaclizumabQ412920
about
Fibrosis in Renal AllograftsDaclizumab Experience in Pediatric Heart TransplantIslet Allotransplantation With Steroid Free ImmunosuppressionA Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant RecipientsYttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s LymphomaAn Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple SclerosisSafety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple SclerosisStudy of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple SclerosisPilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
P4844
Q61917826-F175B076-EAC4-4840-965A-1776DD846C92Q61918458-4EA9E42F-D770-4C19-89E4-A6101907B621Q61924453-E20067B2-45C2-4615-83AA-12ECA51AB5A8Q61934737-F6A87F14-195E-4AA4-BBBD-732D89E5D237Q61956003-90C86699-D98A-45B2-9007-1008774B3D7EQ61957094-9526E843-7AEA-4670-99E7-6E0491ED20C3Q61980620-14CAD9CB-F968-48C3-B7E6-F68CF4A7D741Q62105390-3185B375-BCD2-45F3-99B4-EE486421DA83Q63322627-07CE8C8B-2FB1-474C-9A4C-731353ABD1F0
P4844
description
Protein
@de
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Daclizumab
@de
Daclizumab
@en
Daclizumab
@nl
Daclizumab
@vi
Daklizumab
@pl
Daklizumab
@sh
Daklizumab
@sr
daclizumab
@fr
daclizumab
@it
daclizumab
@pt
type
label
Daclizumab
@de
Daclizumab
@en
Daclizumab
@nl
Daclizumab
@vi
Daklizumab
@pl
Daklizumab
@sh
Daklizumab
@sr
daclizumab
@fr
daclizumab
@it
daclizumab
@pt
altLabel
Anti-IL-2
@en
Humanized antiCD25
@en
Ig gamma-1 chain C region
@en
Ro-24-7375
@en
Zenapax
@it
Zenapax
@pl
prefLabel
Daclizumab
@de
Daclizumab
@en
Daclizumab
@nl
Daclizumab
@vi
Daklizumab
@pl
Daklizumab
@sh
Daklizumab
@sr
daclizumab
@fr
daclizumab
@it
daclizumab
@pt
P2175
P31
P268
P269
P486
P592
P6366
P646
P2115
N0000148541
P2275
Daclizumab
@en
P231
152923-56-3